|
Sep 30
|
3 Magnificent Dividend Stocks to Buy in October
|
|
Sep 29
|
Brinker upgraded, Berkshire Hathaway downgraded: Wall Street's top analyst calls
|
|
Sep 29
|
Pharma Stock Roundup: FDA and EMA Regulatory Updates for ABBV, LLY, SNY & MRK's Drugs
|
|
Sep 29
|
AbbVie Inc. (ABBV) Is a Trending Stock: Facts to Know Before Betting on It
|
|
Sep 29
|
The Zacks Analyst Blog Highlights Oracle, AbbVie, Lowe's Companies, Ecolab and Motorola Solutions
|
|
Sep 29
|
UPDATE 2-AbbVie's blood cancer combo therapy fails in late-stage study
|
|
Sep 29
|
AbbVie Presents Results from Phase 3 CANOVA Study of Venetoclax in Patients with Relapsed or Refractory Multiple Myeloma
|
|
Sep 29
|
Want $500 in Passive Income? Invest $3,500 Into These 3 Dividend Stocks and Wait 4 Years
|
|
Sep 28
|
Top Analyst Reports for Oracle, AbbVie & Lowe's
|
|
Sep 28
|
Is It Worth Investing in AbbVie (ABBV) Based on Wall Street's Bullish Views?
|
|
Sep 26
|
The Big Pharma Stock Trade: Weight Loss Is In, Covid-19 Is Out
|
|
Sep 26
|
AbbVie's (ABBV) Epcoritamab Gets Approval in Europe for DLBCL
|
|
Sep 26
|
AbbVie Inc.'s (NYSE:ABBV) Intrinsic Value Is Potentially 57% Above Its Share Price
|
|
Sep 25
|
AbbVie Announces European Commission Approval of TEPKINLY® (epcoritamab) for Adults with Relapsed or Refractory Diffuse Large B-cell Lymphoma
|
|
Aug 28
|
AbbVie Submits Regulatory Applications to FDA and EMA for Risankizumab (SKYRIZI®) in Ulcerative Colitis
|
|
Aug 27
|
13 Best Defensive Stocks To Buy Now
|
|
Aug 26
|
3 Surprisingly Underrated Stocks to Buy Right Now
|
|
Aug 25
|
CollPlant Biotechnologies Ltd. (NASDAQ:CLGN) Q2 2023 Earnings Call Transcript
|
|
Aug 25
|
The Zacks Analyst Blog Highlights Procter & Gamble, AbbVie, The Walt Disney, HSBC Holdings and Duke Energy
|
|
Aug 25
|
Investors Heavily Search AbbVie Inc. (ABBV): Here is What You Need to Know
|